Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

NCT03984747 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-03-18

No results posted yet for this study

Summary

This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.

Conditions

  • Transplant Rejection
  • Allograft Rejection
  • Complications

Sponsors & Collaborators

  • Natera, Inc.

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-14
Primary Completion
2024-08-23
Completion
2024-08-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984747 on ClinicalTrials.gov